[{"address1": "118 Avenue , 14315", "address2": "Suite 140", "city": "Edmonton", "state": "AB", "zip": "T5L 4S6", "country": "Canada", "phone": "250 744 2487", "fax": "250 708 4345", "website": "https://www.auriniapharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.", "fullTimeEmployees": 300, "companyOfficers": [{"maxAge": 1, "name": "Mr. Peter S. Greenleaf M.B.A.", "age": 53, "title": "President, CEO & Director", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 1573362, "exercisedValue": 0, "unexercisedValue": 4336000}, {"maxAge": 1, "name": "Mr. Joseph M. Miller CPA", "age": 49, "title": "Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 883190, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew Maxwell Donley M.B.A.", "age": 54, "title": "Executive Vice President of Operations & Strategy", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 901844, "exercisedValue": 0, "unexercisedValue": 772500}, {"maxAge": 1, "name": "Mr. Stephen P. Robertson", "age": 41, "title": "Executive VP, General Counsel, Corporate Secretary & Chief Compliance Officer", "yearBorn": 1982, "fiscalYear": 2023, "totalPay": 836382, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Andrea Levin Christopher", "title": "Head of the Corporate Communications & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael R. Martin", "age": 51, "title": "Chief Business Officer", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 350570, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sue  Evans", "title": "Senior Vice President of Global Regulatory Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Scott  Habig", "age": 63, "title": "Chief Commercial Officer", "yearBorn": 1960, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. DeDe  Sheel", "title": "Vice President of Investor Relation", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 4, "compensationRisk": 4, "shareHolderRightsRisk": 2, "overallRisk": 3, "governanceEpochDate": 1717200000, "compensationAsOfEpochDate": 1703980800, "irWebsite": "http://www.isotechnika.com/for_investors/", "maxAge": 86400, "priceHint": 2, "previousClose": 5.65, "open": 5.61, "dayLow": 5.4, "dayHigh": 5.7, "regularMarketPreviousClose": 5.65, "regularMarketOpen": 5.61, "regularMarketDayLow": 5.4, "regularMarketDayHigh": 5.7, "beta": 1.416, "forwardPE": 11.787234, "volume": 1413468, "regularMarketVolume": 1413468, "averageVolume": 1341214, "averageVolume10days": 1157820, "averageDailyVolume10Day": 1157820, "bid": 5.49, "ask": 5.58, "bidSize": 100, "askSize": 200, "marketCap": 792325312, "fiftyTwoWeekLow": 4.71, "fiftyTwoWeekHigh": 12.43, "priceToSalesTrailing12Months": 4.139479, "fiftyDayAverage": 5.2306, "twoHundredDayAverage": 7.02865, "currency": "USD", "enterpriseValue": 559525952, "profitMargins": -0.32686, "floatShares": 127083242, "sharesOutstanding": 143019008, "sharesShort": 11533429, "sharesShortPriorMonth": 11392512, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0806, "heldPercentInsiders": 0.070700005, "heldPercentInstitutions": 0.40386, "shortRatio": 8.54, "shortPercentOfFloat": 0.081099994, "impliedSharesOutstanding": 143019008, "bookValue": 2.502, "priceToBook": 2.2142286, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -62563000, "trailingEps": -0.43, "forwardEps": 0.47, "enterpriseToRevenue": 2.923, "enterpriseToEbitda": -11.905, "52WeekChange": -0.42110765, "SandP52WeekChange": 0.24711585, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "AUPH", "underlyingSymbol": "AUPH", "shortName": "Aurinia Pharmaceuticals Inc", "longName": "Aurinia Pharmaceuticals Inc.", "firstTradeDateEpochUtc": 1409751000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "6af70c53-6225-3411-b004-ce20a00fb8bf", "messageBoardId": "finmb_882669", "gmtOffSetMilliseconds": -14400000, "currentPrice": 5.54, "targetHighPrice": 15.0, "targetLowPrice": 6.0, "targetMeanPrice": 10.86, "targetMedianPrice": 11.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 319367008, "totalCashPerShare": 2.239, "ebitda": -47000000, "totalDebt": 88537000, "quickRatio": 4.902, "currentRatio": 5.605, "totalRevenue": 191407008, "debtToEquity": 24.629, "revenuePerShare": 1.333, "returnOnAssets": -0.08103, "returnOnEquity": -0.16686001, "freeCashflow": 14525125, "operatingCashflow": -20389000, "revenueGrowth": 0.462, "grossMargins": 0.88817, "ebitdaMargins": -0.24555, "operatingMargins": -0.13061, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-18"}]